Vanguard National Trust
PRME icon

Vanguard National Trust’s Prime Medicine PRME Stock Holding History

Vanguard National Trust’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-334
Closed -$1.16K – 815
2026
Q1 		$1.16K Buy
+334
New +$1.27K ﹤0.01% 706

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard National Trust's PRME Position: Q2 2026 in Review

Vanguard National Trust sold out of Prime Medicine (PRME) in Q2 2026, closing a stake of 334 shares — an estimated $1.16K sold.

Vanguard National Trust first reported a position in PRME in Q1 2026 and held it in 1 quarter. The position peaked at $1.16K in Q1 2026. 186 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Vanguard National Trust reported no remaining Prime Medicine position as of Q2 2026 after selling out during the quarter.
  • Vanguard National Trust sold 334 Prime Medicine shares in Q2 2026, an estimated $1.16K.
  • Vanguard National Trust first reported a position in Prime Medicine in Q1 2026 and held it in 1 quarter.
  • Vanguard National Trust's Prime Medicine position peaked at $1.16K in Q1 2026.
  • 186 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.